|
[1]
|
Maeda, D., Dotare, T., Matsue, Y., Teramoto, K., Sunayama, T., Tromp, J., et al. (2023) Blood Pressure in Heart Failure Management and Prevention. Hypertension Research, 46, 817-833. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Garg, P., Assadi, H., Jones, R., Chan, W.B., Metherall, P., Thomas, R., et al. (2021) Left Ventricular Fibrosis and Hypertrophy Are Associated with Mortality in Heart Failure with Preserved Ejection Fraction. Scientific Reports, 11, Article No. 617. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Han, Y., Li, Y., Wu, Z., Pei, Y., Lu, S., Yu, H., et al. (2024) Progress in Diagnosis and Treatment of Hypertension Combined with Left Ventricular Hypertrophy. Annals of Medicine, 56, Article ID: 2405080. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
王嘉怡, 曲艺, 张增磊, 等. 高血压性心脏病的诊断及治疗研究进展[J]. 中国分子心脏病学杂志, 2025, 25(2): 6753-6764.
|
|
[5]
|
Nemtsova, V., Burkard, T. and Vischer, A.S. (2023) Hypertensive Heart Disease: A Narrative Review Series—Part 2: Macrostructural and Functional Abnormalities. Journal of Clinical Medicine, 12, Article 5723. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Aimo, A., Januzzi, J.L., Vergaro, G., Richards, A.M., Lam, C.S.P., Latini, R., et al. (2020) Circulating Levels and Prognostic Value of Soluble ST2 in Heart Failure Are Less Influenced by Age than N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T. European Journal of Heart Failure, 22, 2078-2088. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Zhang, Y., Fan, Z., Liu, H., Ma, J. and Zhang, M. (2020) Correlation of Plasma Soluble Suppression of Tumorigenicity-2 Level with the Severity and Stability of Coronary Atherosclerosis. Coronary Artery Disease, 31, 628-635. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Paker, M., Pichkhadze, E., Miron, D., et al. (2023) Acute Otitis Media Bacteriology in Children Younger Than Three Months in the Last 16 Years. Harefuah, 162, 598-604.
|
|
[9]
|
Wei, P., Liu, L., Wang, X., Zong, B., Liu, X., Zhang, M., et al. (2023) Expression of Soluble ST2 in Patients with Essential Hypertension and Its Relationship with Left Ventricular Hypertrophy. ESC Heart Failure, 10, 303-310. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
靳文英, 史歆然, 于超, 等. 依国人最新超声心动图数据判定左心房大小的方法学比较[J]. 中华超声影像学杂志, 2019, 28(1): 7-11.
|
|
[11]
|
Kockskämper, J. and Pluteanu, F. (2022) Left Atrial Myocardium in Arterial Hypertension. Cells, 11, Article 3157. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
贾慧敏, 关丽娜. 室间隔基底段心肌肥厚作为高血压早期重构影像学标志物的研究进展[J]. 影像研究与医学应用, 2025, 9(7): 17-19.
|
|
[13]
|
Huang, X., Hu, L., Long, Z., Wang, X., Wu, J. and Cai, J. (2024) Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment. Reviews in Cardiovascular Medicine, 25, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chen, J., Xiao, P., Song, D., Song, D., Chen, Z. and Li, H. (2022) Growth Stimulation Expressed Gene 2 (ST2): Clinical Research and Application in the Cardiovascular Related Diseases. Frontiers in Cardiovascular Medicine, 9, Article 1007450. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Arnaldos-Carrillo, M., Noguera-Velasco, J.A., Martínez-Ardil, I.M., Riquelme-Pérez, A., Cebreiros-López, I., Hernández-Vicente, Á., et al. (2023) Value of Increased Soluble Suppressor Tumorigenicity Biomarker 2 (sST2) on Admission as an Indicator of Severity in Patients with Covid-19. Medicina Clínica, 161, 185-191. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Chatterjee, A., Azevedo-Martins, J.M. and Stachler, M.D. (2023) Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights. OncoTargets and Therapy, 16, 675-687. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Farcaş, A.D., Mocan, M., Anton, F.P., Diana, M.L., Chiorescu, R.M., Stoia, M.A., et al. (2020) Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients. Disease Markers, 2020, Article ID: 8143737. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Gizatulina, T.P., Mamarina, A.V., Martyanova, L.U., Belonogov, D.V., Kolunin, G.V., Petelina, T.I., et al. (2024) The Soluble ST2 Level Predicts Risk of Atrial Fibrillation Recurrences in Long-Term Period after Radiofrequency Ablation. BMC Cardiovascular Disorders, 24, Article No. 460. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Sciatti, E., Merlo, A., Scangiuzzi, C., Limonta, R., Gori, M., D’Elia, E., et al. (2023) Prognostic Value of sST2 in Heart Failure. Journal of Clinical Medicine, 12, Article 3970. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Huang, Y., Lin, Y., Fu, M. and Zhang, W. (2025) Diagnostic Efficacy of Soluble ST2 in Pediatric Fulminant Myocarditis. Frontiers in Pediatrics, 13, Article 1417341. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Riccardi, M., Myhre, P.L., Zelniker, T.A., Metra, M., Januzzi, J.L. and Inciardi, R.M. (2023) Soluble ST2 in Heart Failure: A Clinical Role Beyond B-Type Natriuretic Peptide. Journal of Cardiovascular Development and Disease, 10, Article 468. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Zhu, Y., Pei, L., Li, N. and Zhu, Y. (2024) Preoperative sST2 Levels Relate to Myocardial Remodeling and Cardiac Function Improvement after Cardiac Valve Surgery. ESC Heart Failure, 11, 91-98. [Google Scholar] [CrossRef] [PubMed]
|